anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bupropion hydrochloride extended-release tablets (XL), an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is designated as (±)-1-(3-chorophenyl)-2-[(1,1-dimethylethyl)amino]-1­-propanone hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO·HCl. Bupropion hydrochloride powder is white, crystalline, and highly soluble in water. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa. The structural formula is:

Bupropion hydrochloride extended-release tablets, USP (XL) are supplied for oral administration as 150 mg and 300 mg white to off-white extended-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride, USP and the inactive ingredients: povidone, tartaric acid, glyceryl distearate, magnesium stearate, hydroxypropyl cellulose, ethylcellulose, methacrylic acid copolymer dispersion and colloidal silicon dioxide. The tablets are printed with black ink comprising of shellac glaze (modified) in SD-45, isopropyl alcohol, black iron oxide non-irradiated, n-butyl alcohol, propylene glycol and ammonium hydroxide.

The insoluble shell of the extended-release tablet may remain intact during gastrointestinal transit and is eliminated in the feces.

Meets USP Dissolution Test #4.
Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with fluoroquinolones, including levofloxacin. These reactions often occur following the first dose. Some reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema (including tongue, laryngeal, throat, or facial edema/swelling), airway obstruction (including bronchospasm, shortness of breath, and acute respiratory distress), dyspnea, urticaria, itching, and other serious skin reactions. Levofloxacin should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Serious acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see Adverse Reactions (6); Patient Counseling Information (Error! Hyperlink reference not valid.)].
A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
The invention relates to a traditional Chinese medicine for treating goat dysentery as well as preparation method and application thereof. The traditional Chinese medicine for treating goat dysentery is prepared from the following main raw materials in parts by weight: 20-30 parts of pine needle, 15-20 parts of sowthistle tasselflower herb and 30-50 parts of wormwood. The preparation method comprises the following steps: crushing the pine needle, the sowthistle tasselflower herb and the wormwood by using a crusher or manually, mixing the crushed materials accounting for 1%-3% of the total weight of the fodder with goat fodder, and feeding the goat. The traditional Chinese medicine for treating goat dysentery is prepared from the pine needle, the sowthistle tasselflower herb and the wormwood according to the modern Chinese medicine matching. The pine needle can be used for enhancing the goat immunity; the sowthistle tasselflower herb can be used for treating dysentery and diarrhea; the wormwood can be used for rescuing from collapse by restoring yang. The traditional Chinese medicine mixed fodder when being used for feeding goats can play roles in treating dysentery and diarrhea and enhancing the immunity. The traditional Chinese medicine can be used for curing goat dysentery efficiently, has a short treatment course, fast effect, difficulty in relapse, wide source of the raw materials, low cost and no obvious side effect. The preparation process is simple, consumes no energy and generates no gas and wastewater to pollute the environment.
Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
NEW MATERIAL:A plasminogen activator derivative consisting of a polypropylene glycol having a molecular weight of 200-20,000 and bonded through a coupling agent to the amino acid side chain of a human-originated plasminogen activator free of antigenicity. EXAMPLE:Urokinase modified with polypropylene glycol-4-chloro-6-hydroxy-1,3,5- triazine. USE:A thrombolytic agent and antithrombogenetic agent having high physical stability and long duration of the activity. PREPARATION:The titled derivative is prepared by bonding a polypropylene glycol having a molecular weight of 200-20,000, preferably 1,000-10,000 with a coupling agent (e.g. cyanuryl halide), and reacting the product with a human- originated plasminogen activator free of antigenicity. The reaction is preferably carried out at 5-9pH at low temperature.
Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
OBJECTIVE: This study aimed to assess the association between active glycemic management and large for gestational age (LGA) neonates and cesarean delivery (CD) among pregnant women with impaired fasting glucose (IFG).
STUDY DESIGN: Retrospective cohort study using electronic health record data of women with IFG who delivered at the Kaiser Permanente Northern California from 2012 to 2017. IFG was defined as isolated fasting glucose ≥95 mg/dL. Women with gestational diabetes mellitus (GDM) or in whom GDM could not be ruled out were excluded. Baseline and treatment characteristics, and pregnancy outcomes were compared among women with IFG who participated in telephonic home glucose monitoring and glycemic management through a centralized standardized program (participants) with those who did not participate (nonparticipants). The relative risks (RRs) of perinatal complications associated with participation versus nonparticipation were estimated with Poisson's regression models.
RESULTS: We identified 1,584 women meeting inclusion criteria of whom 1,151 (72.7%) were participants and 433 (27.3%) were nonparticipants. There were no differences between groups in baseline characteristics or comorbidities, except for higher mean levels of fasting glucose (FG) at the time of IFG diagnosis in participants than in nonparticipants (98.9 vs. 98.0 mg/dL, p = 0.01). Participants received hypoglycemic medications more frequently than nonparticipants (68.2 vs. 0.9%, p < 0.01). The rate of LGA was significantly lower in participants compared with nonparticipants (19.1 vs. 25.0%, p = 0.01). After adjusting for age, race/ethnicity, education, body mass index, and level of FG impairment, the RR for LGA for participants compared with nonparticipants was 0.68, 95% CI: 0.55-0.84. The risk of CD did not differ significantly by participation status, in unadjusted or adjusted analyses.
CONCLUSION: Active standardized glycemic management was associated with a decreased risk of LGA for women with IFG. This finding supports an active glycemic management strategy for patients with IFG during pregnancy to reduce the risk of LGA, similar to GDM management.
KEY POINTS: · Pregnant women with IFG have increased rates of LGA.. · Active management of IFG is associated with a decreased LGA.. · Treatment of IFG like GDM may improve perinatal outcomes..
A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I \& IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol. Phase I subjects will be healthy volunteers, recruited by an advertisement. Phase IIA subjects will be hyperlipidemic (having high cholesterol), and will be referred to us by their Wound Care Center Physicians. Patients will be randomized to receive placebo pills, (400 or 800 mg) TCT pills, low-dose 81 mg aspirin (commonly used for secondary prevention of stroke), or TCT and aspirin together. Potential subjects for Phase-I who meet study criteria and agree to participate will be in the study for 6 months and have the following study related procedures, blood draw total 4 times, tape stripping (non-invasive procedure), BMI, and blood pressure measurement at each visit (every month). Participants in Phase-IIA will have blood drawn a total of 6 times, tape stripping, BMI and blood pressure measurement and participants will be in the study for 13 months.
A late post-traumatic seizure (LPTS), a consequence of traumatic brain injury (TBI), can potentially evolve into a lifelong condition known as post-traumatic epilepsy (PTE). Presently, the mechanism that triggers epileptogenesis in TBI patients remains elusive, inspiring the epilepsy community to devise ways to predict which TBI patients will develop PTE and to identify potential biomarkers. In response to this need, our study collected comprehensive, longitudinal multimodal data from 48 TBI patients across multiple participating institutions. A supervised binary classification task was created, contrasting data from LPTS patients with those without LPTS. To accommodate missing modalities in some subjects, we took a two-pronged approach. Firstly, we extended a graphical model-based Bayesian estimator to directly classify subjects with incomplete modality. Secondly, we explored conventional imputation techniques. The imputed multimodal information was then combined, following several fusion and dimensionality reduction techniques found in the literature, and subsequently fitted to a kernel- or a tree-based classifier. For this fusion, we proposed two new algorithms: recursive elimination of correlated components (RECC) that filters information based on the correlation between the already selected features, and information decomposition and selective fusion (IDSF), which effectively recombines information from decomposed multimodal features. Our cross-validation findings showed that the proposed IDSF algorithm delivers superior performance based on the area under the curve (AUC) score. Ultimately, after rigorous statistical comparisons and interpretable machine learning examination using Shapley values of the most frequently selected features, we recommend the two following magnetic resonance imaging (MRI) abnormalities as potential biomarkers: the left anterior limb of internal capsule in diffusion MRI (dMRI), and the right middle temporal gyrus in functional MRI (fMRI).
Cardiac conduction abnormalities have occurred during treatment with octreotide. In patients with acromegaly, bradycardia (<50 bpm) developed in 25%, conduction abnormalities occurred in 10% and arrhythmias occurred in 9% of patients during treatment with octreotide. Other ECG changes observed included QT prolongation, axis shifts, early repolarization, low voltage, R/S transition, and early R wave progression. These ECG changes may occur in patients with acromegaly. In one patient with acromegaly and severe congestive heart failure (CHF), initiation of octreotide resulted in worsening of CHF with improvement when drug was discontinued and worsened when octreotide was restarted [see Adverse Reactions (6)]. Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.4)].
This is a pilot study designed to provide initial effect size estimates for an intervention addressing hazardous drinking and sexual risk behavior among men who have sex with men. In this study, 24 participants initially recruited through advertisements in the community will be randomly assigned to either Assessment Only or Intervention Condition. Those in the Assessment Only condition will complete baseline, 6-week, 3-month and 6-month assessments. Those in the intervention condition will receive a 50-min brief intervention in person followed by 6 weeks of tailored app-based messaging to support the intervention content, then another 6-weeks of goal setting text-based messages. Data will be analyzed to determine effect sizes of the intervention on key alcohol use and sex risk outcomes. The primary outcome will be 3-month outcomes, controlling for corresponding baseline outcomes.
Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
1280631 Pressure-sensitive adhesive coatings T J SMITH & NEPHEW Ltd 8 July 1969 [9 July 1968 22 Oct 1968 20 Dec 1968] 32588/68 50045/68 and 60756/68 Heading B2E [Also in Division C3] A moisture vapour permeable pressure-sensitive adhesive material for use on animal skin and nails comprises a backing material having a pressure-sensitive adhesive on at least substantially the whole of the body adhering portion of at least one surface of the backing material, the backing material and adhesive being moisture vapour permeable and unaffected by water and at least one of the backing material and adhesive comprising a synthetic polymer and being continuous and non-permeable to liquid water, the adhesive material having a moisture vapour permeability of at least 300 g./s. metre/24 hours/40C./80% RH. Adhesives may be formed from polymers containing hydrophilic groups such as hydroxyl, carboxyl, amine, amide, ether and alkoxy providing that they are not soluble or highly swollen in water. Water-soluble or water-swellable polymers can be added to permeable pressure-sensitive adhesive formulations to increase their permeability provided they are compatible and do not cause the adhesives to be affected by water, for example a polyvinyl methylether may be added to a polyvinyl ethylether adhesive or a hydroxyl propyl acrylate homopolymer may be added to a compatible pressure-sensitive adhesive. Where a continuous adhesive is used it may be applied in solution, aqueous dispersion or as a hot melt by transfer, knife, roller or curtain coating methods. The adhesive may be made porous by foaming, leaching of soluble fillers, pattern spreading, spraying or selective layer perforating. Where the backing material is continuous it may be a film of a thermoplastic polyurethane or other polymers containing non-bound hydrophylic groups. A preferred backing material is a copolymer of a hydroxy alkyl acrylate or methacrylate with an alkoxy alkyl acrylate or methacrylate optionally with a minor amount of a further polymer. Suitable materials are listed as well as suitable copolymers of acrylic, methacrylic acids and derivatives of these. Where the backing material is not continuous any material having a high moisture vapour permeability may be used such as microporous films of plasticised polyvinyl chloride and non-woven, woven and knitted porous fabrics. The fabrics may be based on cellulose or synthetic polymer fibres which may be crimped and/or laid down so as to give an elastic fabric. Spun-bonded polyester fabrics are particularly suitable. The adhesive may be applied directly to the backing material or a water vapour permeable tie coat which may be continuous or discontinuous may be necessary. A suitable tie coat may be of nylon, or butadiene-vinyl pyridine. A protector may be provided to cover the adhesive prior to use. Alternatively, a release coat may be applied on the reverse side of the backing material.
The present invention discloses a preparation method of a polyelectrolyte composite nano micelle as a drug carrier. Malic acid (MA), lactic acid (LA) and PEG (polyethylene glycol) are used as raw materials, tin(II) dichloride dihydrate is used as a catalyst for direct co polycondensation reaction to obtain an amphiphilic polyelectrolyte terpolymer; then anticancer drug doxorubicin and the amphiphilic polyelectrolyte terpolymer are compounded in aqueous solution to form the nano micelle by interaction between anion and cation. The nano micelle is subjected to in vitro drug release studies. The nano micelle has the characteristics that the drug doxorubicin is involved in micelle formation, and is part of the micelle. The nano micelle has the advantages of high drug loading rate, no drug leakage, reduction of the side effects of drugs, improvement of the bioavailability of the drugs, and the like. The release process has obvious sustained release property, the release rate is controlled by the pH value and the ionic strength of a medium, and the cumulative release rate is as high as 94%.
Many drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of co-administered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the co-administered drug. There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline hydrochloride may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline hydrochloride is withdrawn from co-therapy, an increased dose of the co-administered drug may be required (see Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder under PRECAUTIONS).
The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap. In various embodiments, the RNAi agents comprise a first and a second strand, wherein each strand is a 30-mer or shorter, the first strand comprises ribonucleotides, and the second strand comprises ribonucleotides and one or more spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand. In some embodiments, the 3 end of both strands further comprise, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker; and a 3 end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3 end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the first two base-pairing nucleotides on the 3 end of the one or both strand are 2-MOE. Optionally, the RNAi agent can be modified on one or both 5 end. Optionally, the first or second strand is the sense strand, and the sense strand can comprise a 5 end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.